Adam Crystal, MD, PhD
Tango Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Crystal, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:55 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06810544 · Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossTango Therapeutics, Inc. · recruiting · Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant · study director
- Ph1/Ph2NCT06065059 · Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsTango Therapeutics, Inc. · terminated · Breast Cancer, Ovarian Cancer, Pancreas Cancer · study director
- Ph1/Ph2NCT05887492 · Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsTango Therapeutics, Inc. · active not recruiting · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.